Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Cost of sales as % of net product sales by Quarter
Cost of sales as % of net product sales (%) (%)
Moderna Cost of sales as % of net product sales: 74.0% in Q2 2026, down 31.0 pts from a year earlier.
Latest, Q2 2026
74.0%
Period ended Jun 30, 2026
Change on a year earlier
-31.0 pts
105.0% in Q2 2025
History
22 quarters
Since Q4 2020
Sources
20
Documents cited below
Where the Q2 2026 figure comes from
“Cost of sales as a percentage of net product sales and stand-ready manufacturing revenue for the three months ended June 30, 2026 was 74%, compared to 91% for the same period in 2025.”
Source: Q2 2026 10-Q ↗
Reported in Form 10-Q / 10-K MD&A & Form 8-K Earnings Releases.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cost of sales as % of net product sales (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 74.0% | -31.0 pts | Q2 2026 10-Q ↗ |
| Q1 2026 | Mar 31, 2026 | 249.0% | +145.0 pts | Q1 2026 10-Q ↗ |
| Q3 2025 | Sep 30, 2025 | 21.0% | -7.0 pts | Q3 2025 10-Q ↗ |
| Q2 2025 | Jun 30, 2025 | 105.0% | +43.0 pts | Q2 2025 10-Q ↗ |
| Q1 2025 | Mar 31, 2025 | 104.0% | +46.0 pts | Q1 2025 10-Q ↗ |
| Q4 2024 | Dec 31, 2024 | 79.0% | +46.0 pts | Q4 2024 Earnings Release (8-K) ↗ |
| Q3 2024 | Sep 30, 2024 | 28.0% | -100.0 pts | Q3 2024 Earnings Release (8-K) ↗ |
| Q2 2024 | Jun 30, 2024 | 62.0% | -187.0 pts | Q2 2024 Earnings Release (8-K) ↗ |
| Q1 2024 | Mar 31, 2024 | 58.0% | +15.0 pts | Q1 2024 10-Q ↗ |
| Q4 2023 | Dec 31, 2023 | 33.0% | -6.0 pts | Q4 2023 Earnings Release (8-K) ↗ |
| Q3 2023 | Sep 30, 2023 | 128.0% | +93.0 pts | Q3 2023 10-Q ↗ |
| Q2 2023 | Jun 30, 2023 | 249.0% | +219.0 pts | Q2 2024 Earnings Release (8-K) ↗ |
| Q1 2023 | Mar 31, 2023 | 43.0% | +26.0 pts | Q1 2023 10-Q ↗ |
| Q4 2022 | Dec 31, 2022 | 39.0% | +25.0 pts | Q4 2022 Earnings Release (8-K) ↗ |
| Q3 2022 | Sep 30, 2022 | 35.0% | +20.0 pts | Q3 2022 Earnings Release (8-K) ↗ |
| Q2 2022 | Jun 30, 2022 | 30.0% | +12.0 pts | Q2 2022 10-Q ↗ |
| Q1 2022 | Mar 31, 2022 | 17.0% | +6.0 pts | Q1 2022 10-Q ↗ |
| Q4 2021 | Dec 31, 2021 | 14.0% | +10.0 pts | Q4 2021 Earnings Release (8-K) ↗ |
| Q3 2021 | Sep 30, 2021 | 15.0% | – | Q3 2021 Earnings Release (8-K) ↗ |
| Q2 2021 | Jun 30, 2021 | 18.0% | – | Q2 2021 10-Q ↗ |
| Q1 2021 | Mar 31, 2021 | 11.0% | – | Q1 2021 10-Q ↗ |
| Q4 2020 | Dec 31, 2020 | 4.0% | – | Q4 2021 Earnings Release (8-K) ↗ |
Cite this data
StockData. (2026). Moderna Cost of sales as % of net product sales (%), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/cos-pct-sales
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.